Building A Biopharma Product's Reimbursement Into Deals

The growing influence of payors means biopharma companies are grappling with how to incorporate the impact of reimbursement on a product’s market opportunity when structuring deals, executives said at the BIO-Windhover Pharmaceutical Strategic Outlook conference in New York City in February 2010.

The growing influence of payors means biopharma companies are grappling with how to incorporate the impact of reimbursement on a product's market opportunity when structuring deals, executives said at the BIO-Windhover Pharmaceutical Strategic Outlook conference in New York City on February 24.

For several years, pharma has been slowly, and sometimes inconsistently, incorporating reimbursement concerns into clinical development programs at earlier stages...

In Vivo Podcast

Candid conversations with C-suite leaders.

Keep up with strategy, innovation and evolving trends across life science industries.

More from In Vivo Archive

More from In Vivo